Bioextrax AB AI Stock Analysis
Want to see SE:BIOEX full AI Analyst Report?
Bioextrax AB (BIOEX) AI Stock Analysis
Bioextrax AB
(Nasdaq OMX AB:BIOEX)
The overall score is constrained by the company's weak financial health, marked by persistent losses and cash burn, which is the most significant factor. While the stock shows some positive short-term price momentum, it is approaching overbought levels. The negative P/E ratio further underscores the lack of current profitability.
Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 131.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 70.38K
- Price to Earnings (P/E)
- -6.2
- Beta (1Y)
- 0.85
- Revenue Growth
- -37.50%
- EPS Growth
- 1.01%
- Country
- Sweden
- Employees
- 14
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Biotechnology
Bioextrax AB Business Overview & Revenue Model
Company Description
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules...
Bioextrax AB Financial Statement Overview
Summary
Financial performance is weak. The company has minimal and volatile revenue, persistent losses, and deeply negative cash flows. The only mitigating factor is a debt-free balance sheet, but equity is declining due to ongoing cash burn.
Income Statement
12Very NegativeBalance Sheet
35NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 360.00K | 757.00K | 515.00K | 2.06M | 395.00K | 275.76K |
| Gross Profit | -14.84M | -16.43M | -915.00K | 718.00K | -18.64M | -11.29M |
| EBITDA | -14.16M | -17.24M | -16.18M | -20.65M | -18.19M | -10.18M |
| Net Income | -14.24M | -17.70M | -17.34M | -21.51M | -18.67M | -10.53M |
Balance Sheet | ||||||
| Total Assets | 14.49M | 24.73M | 29.00M | 22.52M | 37.92M | 12.64M |
| Cash, Cash Equivalents and Short-Term Investments | 7.39M | 3.93M | 17.27M | 13.40M | 27.53M | 8.98M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.51M | 3.51M | 2.94M | 1.98M | 6.15M | 5.14M |
| Stockholders Equity | 11.98M | 21.21M | 26.06M | 20.54M | 31.77M | 7.50M |
Cash Flow | ||||||
| Free Cash Flow | -23.61M | -26.20M | -18.99M | -24.41M | -24.38M | -9.45M |
| Operating Cash Flow | -23.34M | -26.05M | -18.78M | -23.31M | -17.60M | -8.48M |
| Investing Cash Flow | -277.00K | -152.00K | -215.00K | -1.10M | -6.78M | -975.13K |
| Financing Cash Flow | 12.58M | 12.86M | 22.86M | 10.28M | 42.94M | 16.38M |
Bioextrax AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Positive. The current price of 2.67 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.33, and above the 200-day MA of 2.53, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 72.00 is Negative, neither overbought nor oversold. The STOCH value of 75.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOEX.
Bioextrax AB Peers Comparison
Overall Rating
SE:BIOEX49Neutral
SE:NXTCL46Neutral
SE:ANNX44Neutral
SE:SPAGO42Neutral
SE:BIOVIC.B41Neutral
SE:XINT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 49Neutral | SEK 131.80M | -6.15 | -116.56% | ― | -37.50% | 1.01% | |
| 46Neutral | SEK 30.33M | -0.63 | -81.23% | ― | -4.02% | 35.86% | |
| 44Neutral | SEK 78.81M | -2.05 | ― | ― | ― | 7.33% | |
| 42Neutral | SEK 35.93M | -1.13 | -87.37% | ― | -97.52% | 31.31% | |
| 41Neutral | SEK 87.79M | -1.22 | -75.51% | ― | 56.06% | 63.95% | |
| 40Underperform | SEK 120.58M | -2.39 | 245.07% | ― | -38.46% | 9.02% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BIOEX | Bioextrax AB | 2.67 | 0.56 | 26.78% | |
| SE:XINT | Xintela AB | 0.14 | -0.11 | -44.22% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.30 | -0.28 | -47.59% | |
| SE:NXTCL | NextCell Pharma AB | 0.24 | -0.56 | -69.81% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.07 | -61.21% | |
| SE:ANNX | Annexin Pharmaceuticals AB | 9.04 | -15.98 | -63.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
